AI Article Synopsis
- After treating B16F10 tumors with immunotherapy, around 60% of mice show a strong antibody response to tumor cell-surface antigens.
- The antibodies from these mice can provide protection against future challenges with B16F10 cells and can also react with other similar tumor cell lines.
- The envelope glycoprotein of a murine endogenous retrovirus has been identified as the main target of this antibody response, indicating potential for similar vaccines against human cancers expressing related proteins.
Article Abstract
Following curative immunotherapy of B16F10 tumors, ~60% of mice develop a strong antibody response against cell-surface tumor antigens. Their antisera confer prophylactic protection against intravenous challenge with B16F10 cells, and also cross-react with syngeneic and allogeneic tumor cell lines MC38, EL.4, 4T1, and CT26. We identified the envelope glycoprotein (env) of a murine endogenous retrovirus (ERV) as the antigen accounting for the majority of this humoral response. A systemically administered anti-env monoclonal antibody cloned from such a response protects against tumor challenge, and prophylactic vaccination against the env protein protects a majority of naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells. These results suggest the potential for effective prophylactic vaccination against analogous HERV-K env expressed in numerous human cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049297 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0248903 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!